SCHEMBL7140621

SCHEMBL7140621

Cc1ccc(COc2ccc(C=C3SC(=S)N(C(C(=O)O)c4ccccc4)C3=O)c(OCc3ccc(C)cc3)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.68
MEN1 O00255 6/20 0.68
KMT2A Q03164 6/20 0.68
ADAMTS5 Q9UNA0 3/20 0.64
MAPK1 P28482 3/20 0.61
ALDH1A1 P00352 3/20 0.56
RECQL P46063 2/20 0.56
KDM4E B2RXH2 1/20 0.56
GLA P06280 1/20 0.56
PTPN1 P18031 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
PPARG P37231 1/20 0.55
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
POLB P06746 3/20 0.54
GAA P10253 2/20 0.54
PTPN2 P17706 1/20 0.54
PTPN6 P29350 1/20 0.54
CDC25B P30305 1/20 0.54
PTPN11 Q06124 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148343 0.94 ADAMTS5 (0.71) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7142548 0.93 MAPT (0.58) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7165592 0.88 MAPT (0.66) MAPTMEN1KMT2AADAMTS5ALDH1A1
SCHEMBL7149430 0.88 PTPN1 (0.54) MAPTMEN1KMT2AADAMTS5ALDH1A1
SCHEMBL7148425 0.88 ADAMTS5 (0.75) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7149413 0.85 ADAMTS5 (0.62) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7145081 0.84 ADAMTS5 (0.61) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7144791 0.82 ADAMTS5 (0.67) MAPTMEN1KMT2AADAMTS5MAPK1
SCHEMBL7149409 0.82 ADAMTS5 (0.68) MAPTMEN1KMT2AADAMTS5ALDH1A1
SCHEMBL7146810 0.82 PTPN1 (0.54) MAPTMEN1KMT2AADAMTS5MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US claimed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US claimed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP claimed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO claimed
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA MAPT 3924/4885MEN1 936/4885KMT2A 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.